Research Article

Abnormal Movements of Japanese Infants following Treatment with Midazolam in a Neonatal Intensive Care Unit: Incidence and Risk Factors

Table 3

Logistic regression analysis of factors associated with the appearance of abnormal movements.

NumberOdds ratio (95% CI) 𝑃 -value

Sex
 Female381 (Reference)0.12
 Male560.10 (0.01–1.82)
Gestational age (weeks)940.50 (0.21–1.20)0.12
Apgar score 1941.23 (0.37–4.11)0.73
Apgar score 5943.20 (0.88–12.33)0.08
Birth weight (g)941.00 (0.99–1.00)0.46
Postnatal age (days)940.94 (0.86–1.04)0.24
Postconceptional age (weeks)941.00 (0.97–1.03)0.98
Body weight (g)941.00 (0.99–1.00)0.65
Dose of midazolam (mg/kg/h)94<0.001 (<0.001–>999.999)0.26
Birth asphyxia0.03
 No641 (Reference)
 Yes30108.04 (1.50–>999.999)
Intracranial hemorrhage0.27
 No861 (Reference)
 Yes85.41 (0.27–109.63)
Neonatal seizure0.32
 No871 (Reference)
 Yes710.99 (0.09–>999.999)
Hypocalcemia0.88
 No681 (Reference)
 Yes260.83 (0.077–8.98)
Vitamin K deficiency0.78
 No811 (Reference)
 Yes130.62 (0.02–17.04)
Hydrocephalus0.99
 No911 (Reference)
 Yes3<0.001 (<0.001–>999.999)
Apnea0.65
 No851 (Reference)
 Yes90.37 (0.005–28.49)
Hypoxia0.99
 No911 (Reference)
 Yes3<0.001 (<0.001–>999.999)

CI, confidence interval.